Table 3.
Univariate and multivariate Cox regression analysis of clinical pathologic features for OS.
| Variables | Univariate Cox Regression | Multivariate Cox Regression | ||||||
|---|---|---|---|---|---|---|---|---|
| Training Group | Validation Group | Training Group | Validation Group | |||||
| HR | p-Value | HR | p-Value | HR | p-Value | HR | p-Value | |
| Age | 1.90599 | 0.00480 | 1.87244 | 0.00712 | 2.01716 | 0.00923 | 1.89282 | 0.00942 |
| Gender | 1.33404 | 0.28459 | 0.89624 | 0.68090 | 1.21995 | 0.49531 | 0.90684 | 0.72394 |
| Stage | 2.57129 | 0.00077 | 2.31364 | 0.00483 | 1.70227 | 0.08188 | 2.02544 | 0.02310 |
| TTN | 0.91655 | 0.69983 | 0.88862 | 0.61304 | 1.02461 | 0.92293 | 0.81568 | 0.43476 |
| TP53 | 0.96076 | 0.85924 | 0.75083 | 0.22132 | 1.17030 | 0.54285 | 0.61782 | 0.04981 |
| MUC16 | 0.91318 | 0.73605 | 0.99522 | 0.98484 | 1.27489 | 0.43391 | 1.48957 | 0.14201 |
| Risk Score | 4.32931 | 0.00000 | 2.24823 | 0.00035 | 4.02659 | 0.00000 | 1.67008 | 0.02760 |
p < 0.05 was considered statistically significant. HR, hazard ratio. Age (>65 vs. 65<). Gender (female vs. male). Stage (stage I&II vs. stage III&IV). TNN, TP53, MUC16 (mutant vs. wildtype).